NovelStem International (OTCMKTS:NSTM – Get Free Report) is one of 76 publicly-traded companies in the “Diagnostics & Research” industry, but how does it contrast to its competitors? We will compare NovelStem International to related companies based on the strength of its dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Risk & Volatility
NovelStem International has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, NovelStem International’s competitors have a beta of 0.77, indicating that their average stock price is 23% less volatile than the S&P 500.
Insider & Institutional Ownership
30.5% of shares of all “Diagnostics & Research” companies are held by institutional investors. 13.6% of NovelStem International shares are held by insiders. Comparatively, 25.9% of shares of all “Diagnostics & Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NovelStem International | 0 | 0 | 0 | 0 | N/A |
NovelStem International Competitors | 70 | 389 | 352 | 6 | 2.36 |
As a group, “Diagnostics & Research” companies have a potential downside of 0.06%. Given NovelStem International’s competitors higher possible upside, analysts plainly believe NovelStem International has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares NovelStem International and its competitors revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NovelStem International | $10,000.00 | -$4.19 million | -1.05 |
NovelStem International Competitors | $700.37 million | $29.50 million | -193.21 |
NovelStem International’s competitors have higher revenue and earnings than NovelStem International. NovelStem International is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares NovelStem International and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NovelStem International | -9,166.67% | N/A | -73.18% |
NovelStem International Competitors | -424.96% | -827.95% | -22.16% |
Summary
NovelStem International competitors beat NovelStem International on 8 of the 10 factors compared.
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter.